Full Press Release Details
Champions Biotechnology,
855 N. Wolfe Street, Suite 619, Baltimore, Maryland
Champions Biotechnology CFO
Baltimore, MD, January 14,
2011 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a
company with a predictive translational platform aimed at accelerating the
development and enhancing the value of oncology drugs, announced today the
resignation of Mark Schonau, Champions' Chief Financial
Officer. Mr. Schonau indicated that he has no disagreements
with management and has resigned to pursue other opportunities. Champions is
seeking chief financial officer candidates and intends to complete the search
About Champions Biotechnology,
Champions Biotechnology, Inc. is engaged in the development of
advanced translational platforms and tumor specific data to enhance and
accelerate the value of oncology drugs. The Company's Technology Platform
is a novel approach based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the resulting engraftments
(Champions TumorgraftsTM) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest that unlike
traditional xenografts, these Tumorgrafts closely reflect human cancer biology
and their response to drugs is predictive of clinical outcomes in cancer
patients. Champions Biotechnology leverages its preclinical platform to
evaluate drug candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the Company
plans to sell, partner or license them to pharmaceutical and/or biotechnology
companies, as appropriate. The Company also offers its predictive preclinical
platform and tumor specific data to physicians for personalized patient care
and to companies for evaluation of oncology drugs in models that integrate
prognostic testing with biomarker discovery.